235 related articles for article (PubMed ID: 17895381)
1. Molecular basis for passive immunotherapy of Alzheimer's disease.
Gardberg AS; Dice LT; Ou S; Rich RL; Helmbrecht E; Ko J; Wetzel R; Myszka DG; Patterson PH; Dealwis C
Proc Natl Acad Sci U S A; 2007 Oct; 104(40):15659-64. PubMed ID: 17895381
[TBL] [Abstract][Full Text] [Related]
2. Structures of Abeta-related peptide--monoclonal antibody complexes.
Gardberg A; Dice L; Pridgen K; Ko J; Patterson P; Ou S; Wetzel R; Dealwis C
Biochemistry; 2009 Jun; 48(23):5210-7. PubMed ID: 19385664
[TBL] [Abstract][Full Text] [Related]
3. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
van Dyck CH
Biol Psychiatry; 2018 Feb; 83(4):311-319. PubMed ID: 28967385
[TBL] [Abstract][Full Text] [Related]
4. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
[TBL] [Abstract][Full Text] [Related]
5. Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies.
Ramakrishnan M; Kandimalla KK; Wengenack TM; Howell KG; Poduslo JF
Biochemistry; 2009 Nov; 48(43):10405-15. PubMed ID: 19775170
[TBL] [Abstract][Full Text] [Related]
6. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.
Tucker S; Möller C; Tegerstedt K; Lord A; Laudon H; Sjödahl J; Söderberg L; Spens E; Sahlin C; Waara ER; Satlin A; Gellerfors P; Osswald G; Lannfelt L
J Alzheimers Dis; 2015; 43(2):575-88. PubMed ID: 25096615
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
8. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.
Arndt JW; Qian F; Smith BA; Quan C; Kilambi KP; Bush MW; Walz T; Pepinsky RB; Bussière T; Hamann S; Cameron TO; Weinreb PH
Sci Rep; 2018 Apr; 8(1):6412. PubMed ID: 29686315
[TBL] [Abstract][Full Text] [Related]
9. Humoral immune response to fibrillar beta-amyloid peptide.
Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
[TBL] [Abstract][Full Text] [Related]
10. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
Cehlar O; Skrabana R; Revajova V; Novak M
Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
[TBL] [Abstract][Full Text] [Related]
11. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.
Murakami K
Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729
[TBL] [Abstract][Full Text] [Related]
12. Amyloid beta peptide immunotherapy in Alzheimer disease.
Delrieu J; Ousset PJ; Voisin T; Vellas B
Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
[TBL] [Abstract][Full Text] [Related]
13. 'Clinical trials in Alzheimer's disease': immunotherapy approaches.
Delrieu J; Ousset PJ; Caillaud C; Vellas B
J Neurochem; 2012 Jan; 120 Suppl 1():186-193. PubMed ID: 21883222
[TBL] [Abstract][Full Text] [Related]
14. His-tag binding by antibody C706 mimics β-amyloid recognition.
Teplyakov A; Obmolova G; Canziani G; Zhao Y; Gutshall L; Jung SS; Gilliland GL
J Mol Recognit; 2011; 24(4):570-5. PubMed ID: 20842634
[TBL] [Abstract][Full Text] [Related]
15. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
[TBL] [Abstract][Full Text] [Related]
16. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL
Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231
[TBL] [Abstract][Full Text] [Related]
17. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.
Demattos RB; Lu J; Tang Y; Racke MM; Delong CA; Tzaferis JA; Hole JT; Forster BM; McDonnell PC; Liu F; Kinley RD; Jordan WH; Hutton ML
Neuron; 2012 Dec; 76(5):908-20. PubMed ID: 23217740
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic, antigenic, fibrillogenic and inflammatory properties of new simplified beta-amyloid peptides.
Rossi M; Piovesan P; Ghirardi O; Mastroianni D; Bombardi V; Battistini L; Cencioni MT; Capobianco D; Borsini F; Colombo M; Verdoliva A
Mol Immunol; 2009 Aug; 46(13):2524-32. PubMed ID: 19535144
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of the β-amyloid(4-10) epitope of plaque specific Aβ antibodies by affinity-mass spectrometry using alanine site mutation.
Ștefănescu R; Lupu L; Manea M; Iacob RE; Przybylski M
J Pept Sci; 2018 Jan; 24(1):. PubMed ID: 29322650
[TBL] [Abstract][Full Text] [Related]
20. Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.
Söllvander S; Ekholm-Pettersson F; Brundin RM; Westman G; Kilander L; Paulie S; Lannfelt L; Sehlin D
J Alzheimers Dis; 2015; 48(1):63-72. PubMed ID: 26401929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
